GLP‐1 receptor agonists (GLP‐1 RAs), such as liraglutide, semaglutide and tirzepatide, were developed to treat obesity as they promote satiety, delay gastric emptying and enhance glucose‐dependent insulin secretion.5 Here, GLP1R is linked to Obesity.